Oncology News

The FDA granted orphan drug designation to ATG-101 for the treatment of pancreatic cancer, according to a press release from the agent’s manufacturer.

Adagrasib alone and in combination with cetuximab exhibited promising efficacy compared with historical outcomes among heavily pretreated patients with advanced colorectal cancer who had KRASG12C mutations.

Healio presents the following collection of FDA news related to gastroenterology, including the approval of generic diarrhea relief tablets, treatment for acid sphingomyelinase deficiency and biliary tract cancer, and more.

The addition of 18-fluorodeoxyglucose to PET provided significant prognostic benefit in objective assessment of neoadjuvant chemotherapy response among patients with borderline resectable/locally advanced pancreatic cancer.

Data showed that colorectal cancer screening delays of 1 to 2 years because of the COVID-19 pandemic had minimal impact on individuals aged 50 to 60 years, whereas these delays had pronounced impact on those aged 65 years and older.

Patients with familial adenomatous polyposis with ileal pouch-anal anastomosis developed ileal adenomas more often than patients with end ileostomy after proctocolectomy, according to research published in Gastrointestinal Endoscopy.

Investigators have identified an elevated risk for hepatocellular carcinoma in people exposed to per- and polyfluoroalkyl substances, according to a study published in JHEP Reports.

The FDA approved durvalumab with gemcitabine and cisplatin for adults with locally advanced or metastatic biliary tract cancer.

A risk-adapted approach for population-based colorectal cancer screening was a viable and cost-effective option compared with existing colonoscopy and fecal immunochemical test strategies, according to new research in China.

Adjuvant chemotherapy with modified FOLFIRINOX resulted in significantly longer survival vs. gemcitabine among patients with previously resected pancreatic ductal adenocarcinoma, according to 5-year data from a randomized phase 3 study.